No annual revenue total was found in Trevi Therapeutics, Inc.'s SEC filings.
Trevi Therapeutics, Inc. (TRVI) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$42.1 million. As of Jun 30, 2026 it held $318.9 million in cash and investments and $605,000 in total debt.
Revenue
—
Net income (TTM)
$-51.11M
-8.1% vs year-ago TTM
Operating cash flow (TTM)
$-52.63M
-23.3% vs year-ago TTM
Free cash flow (TTM)
$-52.87M
-23.8% vs year-ago TTM
EPS (TTM)
$-0.34
+17.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
128.40M
+32.8% vs prior year
Net cash
$318.26M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TRVI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Haven, CT
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1563880
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$49.3M | -$51.5M | -$33.9M | -$29.9M | -$32.5M |
| Net income | -$42.8M | -$47.9M | -$29.1M | -$29.2M | -$33.9M |
| Diluted EPS | -$0.32 | -$0.47 | -$0.29 | -$0.45 | — |
| Operating cash flow | -$42.1M | -$38.3M | -$31.7M | -$28.2M | -$28.9M |
| Free cash flow | -$42.1M | -$38.3M | -$31.8M | -$28.3M | — |
| Total assets | $193.4M | $110.9M | $89.4M | $123.0M | $38.5M |
| Total liabilities | $10.2M | $11.3M | $6.9M | $15.6M | $21.4M |
| Stockholders' equity | $183.2M | $99.6M | $82.5M | $107.5M | $17.1M |
| Cash and investments | $188.3M | $107.6M | $83.0M | $120.5M | $36.8M |
| Total debt | $753,000 | $1.0M | $1.3M | $27,000 | $144,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 4, 2026 | Jun 3, 2026 |
| 10-Q | Quarterly report | May 5, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 5, 2026 | May 5, 2026 |
| ARS | Annual report to shareholders | Apr 21, 2026 | Dec 31, 2025 |
All 537 Trevi Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.